<DOC>
	<DOC>NCT00883870</DOC>
	<brief_summary>This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.</brief_summary>
	<brief_title>Mesenchymal Stem Cells in Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>Males or females with nonchild bearing potential in the age group of 1860 yrs of Indian origin. Established CLI, clinically and hemodynamically confirmed as per Rutherford II4, III5, or III6; Patients having Infrainguinal arterial occlusive disease with rest pain or ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment (No option patients) Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 70 mm Hg or TcPO2 ≤ 60 mmHg in the foot Patients if having associated Type II Diabetes, should be on medication and well controlled (HbA1c ≤ 8%) without complications Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required followup visits Normal liver and renal function On regular medication for hypertension if any Patients with CLI suitable for surgical or percutaneous revascularization as determined by the surgeon performing vascular procedure and patients with any acute/chronic inflammatory condition CLI patient requiring amputation proximal to transmetatarsal level Patients with gait disturbance for reasons other than CLI. Type I diabetes Patients having respiratory complications/left ventricular ejection fraction &lt; 25%f) Stroke or myocardial infarction within last 3 months Patients who are contraindicated for MRA Have clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy Documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 1 year Patients already enrolled in another investigational drug trial or completed within 3 months. History of severe alcohol or drug abuse within 3 months of screening. Hb% &lt; 10 gm%, Serum Creatinine ≥ 2mg%, Serum Total Bilirubin ≥2mg%, HbA1c &gt; 8% Women with child bearing potential, pregnant and lactating women. Patients tested positive for HIV 1, HCV, HBV,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>mesenchymal stem cells</keyword>
	<keyword>critical limb ischemia</keyword>
</DOC>